Companies
8-K ↗8-K ↗
PCVX
Vaxcyte, Inc.
Vaxcyte develops vaccine candidates using its eCRM platform technology, with a focus on infectious diseases. The company is in the preclinical and clinical trial stages of development, advancing multiple vaccine candidates toward potential commercialization. Vaxcyte's pipeline aims to provide broad coverage against various pathogens through improved immunogenicity compared to existing vaccines.
$57.24+59.71%1Y
PCVX · daily close · illustrative · 0 catalysts marked
Pipeline
Phase 3Pneumococcal Vaccines
Phase 3Pneumococcal Vaccines
Phase 3Pneumococcal Vaccines
Phase 3Pneumococcal Vaccines
Phase 2Pneumococcal Vaccines
Phase 2Pneumococcal Vaccines
Phase 2Pneumococcal Vaccines
Phase 2Pneumococcal Vaccines
Phase 2Pneumococcal Vaccines
UnknownIndication pending review
UnknownIndication pending review
Catalyst Calendar
Past (2)
SEP 03
ReadoutVAX-31
“On September 3, 2024, Vaxcyte, Inc. (the "Company") issued a press release announcing positive topline data from its Phase 1/2 study evaluating the safety, tolerability and immunogenicity of VAX-31, the Company's 31-valent pneumococcal conjugate vaccine candidate designed to prevent invasive pneumococcal disease, in adults aged 50 and older.”
MAR 31
ReadoutVAX-24
“positive topline results from its Phase 2 dose-finding study evaluating the safety, tolerability and immunogenicity of VAX-24, the Company's 24-valent pneumococcal conjugate vaccine candidate designed to prevent invasive pneumococcal disease, in healthy infants”